论文部分内容阅读
临床上充血性心力衰竭患者(NYHA分级Ⅳ级)体力活动受限,卧床时间长,因而静脉血栓形成(VTE)的发生率高,是死亡的重要原因。目前,低分子肝素(LMWH)为公认的预防深静脉血栓形成(DVT)有效药物,但LMWH的疗效及出血风险与用药时间相关性的研究报道较少。本文旨在探讨LMWH预防充血性心
In patients with congestive heart failure (NYHA class Ⅳ), physical activity is limited, bedridden, and therefore high incidence of venous thrombosis (VTE), is an important cause of death. At present, low molecular weight heparin (LMWH) is recognized as an effective drug for the prevention of deep venous thrombosis (DVT), but there are few reports on the efficacy of LMWH and the correlation between the bleeding risk and the time of treatment. This article aims to investigate LMWH to prevent congestive heart